+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Anti-Thrombin III Testing Market 2019-2023 - Product Image

Global Anti-Thrombin III Testing Market 2019-2023

  • ID: 4801838
  • Report
  • July 2019
  • Region: Global
  • 122 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH
  • MORE
Global Anti-Thrombin III Testing Market: About this market

Anti-thrombin III testing is used to determine recurrent abnormal blood clotting and diagnose anti-thrombin deficiency. This Anti-thrombin III testing market analysis considers sales of testing kits to hospitals, laboratories, and academic and research institutions. Our analysis also considers the sales of anti-thrombin III testing in Asia, Europe, North America, and ROW. In 2018, hospitals segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as the rising number of patients with blood disorders and cardiovascular conditions and increasing surgery cases will significantly help the hospitals segment in maintaining its leading market position. Also, our global anti-thrombin III testing report has observed market growth factors such as the existence of tests related to anti-thrombin III, an increasing number of hypertension cases, and rising preference for rapid diagnostics. However, the lack of clinically available protocols to treat anti-thrombin deficiency, stringent regulations, and limited access to diagnostic procedures in developing nations may hamper the growth of the anti-thrombin III testing industry over the forecast period.

Global Anti-Thrombin III Testing Market: Overview

The shift toward rapid diagnostics

All anti-thrombin III testing products support rapid diagnostic tests (RDTs). RDTs are gaining popularity as they are easy to use and can screen biological samples quickly to provide results in no time. They are preferred for preliminary or emergency medical screening. As a result, the demand for anti-thrombin III testing products is growing from hospitals and other diagnostic facilities. This demand for anti-thrombin III testing products will lead to the expansion of the global anti-thrombin III testing market at a CAGR of almost 6% during the forecast period.

Presence of various blood clotting disorders

The symptoms of anti-thrombin deficiency are similar to that of other disorders such as antiphospholipid syndrome, protein S deficiency, and protein C deficiency. It is crucial for patients with these indications to rule out or determine anti-thrombin deficiency to receive appropriate treatment. The prevalence of the mentioned health conditions is increasing the sales of anti-thrombin III test kits and solutions. Therefore, this trend will have a positive impact on the overall market growth.

Competitive Landscape

With the presence of few major players, the global anti-thrombin III testing market is moderately concentrated. This robust vendor analysis is designed to help clients in improving their market position, and in line with this, this report provides a detailed analysis of several leading Anti-Thrombin III Testing manufacturers, which include Abbott Laboratories, Danaher Corp., F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc.

Also, the anti-thrombin III testing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY END-USER
  • Market segmentation by end-user
  • Comparison by end-user
  • Hospitals - Market size and forecast 2018-2023
  • Laboratories - Market size and forecast 2018-2023
  • Academic and research institutes - Market size and forecast 2018-2023
  • Market opportunity by end-user
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Presence of various blood clotting disorders
  • Rise in the geriatric population
  • Prevalence of inherited anti-thrombin deficiency
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Abbott Laboratories
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Global healthcare market
Exhibit 02: Segments of global healthcare market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: End-user - Market share 2018-2023 (%)
Exhibit 18: Comparison by end-user
Exhibit 19: Hospitals - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Hospitals - Year-over-year growth 2019-2023 (%)
Exhibit 21: Laboratories - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Laboratories - Year-over-year growth 2019-2023 (%)
Exhibit 23: Academic and research institutes - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Academic and research institutes - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by end-user
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Abbott Laboratories - Vendor overview
Exhibit 46: Abbott Laboratories - Business segments
Exhibit 47: Abbott Laboratories - Organizational developments
Exhibit 48: Abbott Laboratories - Geographic focus
Exhibit 49: Abbott Laboratories - Segment focus
Exhibit 50: Abbott Laboratories - Key offerings
Exhibit 51: Danaher Corp. - Vendor overview
Exhibit 52: Danaher Corp. - Business segments
Exhibit 53: Danaher Corp. - Organizational developments
Exhibit 54: Danaher Corp. - Geographic focus
Exhibit 55: Danaher Corp. - Segment focus
Exhibit 56: Danaher Corp. - Key offerings
Exhibit 57: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 58: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 59: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 60: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 61: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 62: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 63: Siemens Healthcare GmbH - Vendor overview
Exhibit 64: Siemens Healthcare GmbH - Business segments
Exhibit 65: Siemens Healthcare GmbH - Organizational developments
Exhibit 66: Siemens Healthcare GmbH - Geographic focus
Exhibit 67: Siemens Healthcare GmbH - Segment focus
Exhibit 68: Siemens Healthcare GmbH - Key offerings
Exhibit 69: Thermo Fisher Scientific Inc. - Vendor overview
Exhibit 70: Thermo Fisher Scientific Inc. - Business segments
Exhibit 71: Thermo Fisher Scientific Inc. - Organizational developments
Exhibit 72: Thermo Fisher Scientific Inc. - Geographic focus
Exhibit 73: Thermo Fisher Scientific Inc. - Segment focus
Exhibit 74: Thermo Fisher Scientific Inc. - Key offerings
Exhibit 75: Validation techniques employed for market sizing
Exhibit 76: Definition of market positioning of vendors


Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH
  • MORE
The following companies are recognised as the key players in the global anti-thrombin III testing market: Abbott Laboratories, Danaher Corp., F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the presence of various blood clotting disorders.”

According to the report, one of the major drivers for this market is the shift toward rapid diagnostics.

Further, the report states that one of the major factors hindering the growth of this market is the lack of clinically available protocols to treat anti-thrombin deficiency.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Abbott Laboratories
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown
Adroll
adroll